Table 2

Clinical and physiological parameters of patients with acetaminophen-induced acute liver failure (AALF) and non-acetaminophen induced AALF (NAALF)

ParameterAALFNAALF
Number of patients239
Number of patients transplanted/died8/234/9
MERTK monocyte expression (%)51.50**
[40.75–73.75]
35.95
[31.45–52.25]
WCC
(×109/L)
9.57
[6.34–15.96]
11.4
[8.0–18.4]
Monocytes
(×109/L)
0.21**
[0.14–0.36]
0.54
[0.31–0.98]
Creatinine
(μmol/L)
148
[76.5–237.5]
193
[93–362]
INR6.4**
[3.0–8.4]
2.7
[1.4–4.6]
Bilirubin
(μmol/L)
74
[48–96]
172
[42.5–587]
Lactate
(mmol/L)
3.0
[2.2–6.8]
2.7
[1.8–4.0]
AST
(IU/mL)
5172*
[1500–7436]
2088
[432–6176]
Encephalopathy2*
[1–3]
1
[1–2]
SIRS score2
[1–3]
2
[0–3]
APACHE II19
[14–25.5]
20
[11–27]
SOFA12
[10–15.5]
13
[10–16.5]
MELD40
[33–40]
38
[24–40]
  • *p<0.05 and **p<0.01, compared with NAALF group.

  • APACHE II, Acute Physiology and Chronic Health Evaluation II score; AST, aspartate aminotransferase; INR, international normalised ratio; MELD, Model for End Stage Liver Disease; SIRS, systemic inflammatory response syndrome; SOFA, Sequential Organ Failure Assessment score; WCC, white (leucocyte) cell count.